Adaptimmune Therapeutics plc
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2021 | — | $309.2M | $32.4M |
| Jun 2021 | — | $277.9M | $50.5M |
| Sep 2021 | — | $241.0M | $42.9M |
| Dec 2021 | — | $206.0M | $149.9M |
| Mar 2022 | — | $163.1M | $89.5M |
| Jun 2022 | — | $141.9M | $97.8M |
| Sep 2022 | — | $113.3M | $79.0M |
| Dec 2022 | — | $81.9M | $108.0M |
| Mar 2023 | — | $83.9M | $119.9M |
| Jun 2023 | — | $126.7M | $77.0M |
| Sep 2023 | — | $88.1M | $90.1M |
| Dec 2023 | — | $39.5M | $144.0M |
| Mar 2024 | — | $24.4M | $140.7M |
| Jun 2024 | $25.0M | $96.3M | $211.8M |
| Sep 2024 | $49.9M | $80.0M | $116.7M |
| Dec 2024 | $50.2M | $11.8M | $91.1M |
| Mar 2025 | $25.4M | $-37.4M | $41.1M |
| Jun 2025 | $25.7M | $-71.0M | $26.1M |